📰 Nasdaq Spry News
Nasdaq Spry News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Spry. Real-time updates on events, politics, business and more.
April 20, 2024
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the company’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00. Following the completion of the transaction, the insider now directly owns 1,647,447 shares in […]
April 20, 2024
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $9.28, for a total transaction of $928,000.00. Following the transaction, the insider now directly owns 1,647,447 shares in the company, valued […]
March 29, 2024
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 2,343 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $9.02, for a total value of $21,133.86. Following the completion of the transaction, the insider now owns 1,745,082 shares of the company’s […]
March 26, 2024
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $9.75 and last traded at $9.73, with a volume of 978686 shares trading hands. The stock had previously closed at $9.13. Analyst Ratings Changes Several analysts have issued reports on […]
February 20, 2024
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was upgraded by equities research analysts at William Blair from a “market perform” rating to an “outperform” rating in a report released on Tuesday, MarketBeat Ratings reports. Separately, Wedbush increased their price target on ARS Pharmaceuticals from $5.00 to $13.00 and gave the stock an “outperform” rating in […]
September 22, 2023
Leerink Partnrs cut shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) from an outperform rating to a market perform rating in a research report released on Thursday morning, PriceTargets.com reports. A number of other research analysts have also recently issued reports on the stock. SVB Leerink cut shares of ARS Pharmaceuticals from an outperform rating […]
September 22, 2023
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) was downgraded by equities researchers at Leerink Partnrs from an “outperform” rating to a “market perform” rating in a research note issued on Thursday, PriceTargets.com reports. Other equities analysts also recently issued research reports about the company. William Blair cut ARS Pharmaceuticals from an “outperform” rating to a […]
September 20, 2023
Company aligned with FDA in August 2023 on both physician labeling and post-market requirements, which included a repeat-dose study of neffy under...
September 1, 2023
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) Director Ra Capital Management, L.P. bought 3,750,000 shares of the stock in a transaction that occurred on Tuesday, August 29th. The stock was acquired at an average price of $6.20 per share, for a total transaction of $23,250,000.00. Following the acquisition, the director now directly owns 5,856,774 […]
August 18, 2023
Wedbush restated their outperform rating on shares of ARS Pharmaceuticals (NASDAQ:SPRY – Free Report) in a research report released on Monday morning, Benzinga reports. They currently have a $15.00 target price on the stock. Wedbush also issued estimates for ARS Pharmaceuticals’ Q4 2023 earnings at ($0.16) EPS, FY2024 earnings at ($0.75) EPS, FY2025 earnings at […]